Free Trial

Oncternal Therapeutics (ONCT) Insider Trading & Ownership

Oncternal Therapeutics logo
$0.53 0.00 (0.00%)
As of 04/14/2025

Oncternal Therapeutics (NASDAQ:ONCT) Insider Buying and Selling Activity

Current
Insider Ownership
Percentage
11.20%
Number Of
Insiders Buying
(Last 3 Years)
7
Amount Of
Insider Buying
(Last 3 Years)
$149,215.84
Number Of
Insiders Selling
(Last 3 Years)
0
Get ONCT Insider Trade Alerts

Want to know when executives and insiders are buying or selling Oncternal Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

ONCT Insider Buying and Selling by Quarter

Remove Ads

Oncternal Therapeutics Insider and Congressional Trades History

Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
4/8/2024Robert James WillsDirectorBuy3,086$8.96$27,650.56  
3/28/2024Robert James WillsDirectorBuy6,914$8.48$58,630.72  
2/23/2024David F HaleDirectorBuy714$9.04$6,454.56  
6/14/2023Gunnar F KaufmannInsiderBuy150$7.20$1,080.00  
6/12/2023Gunnar F KaufmannInsiderBuy1,250$7.00$8,750.00  
4/14/2023Salim YazjiInsiderBuy250$6.00$1,500.00  
4/13/2023James B BreitmeyerCEOBuy5,000$5.80$29,000.00  
4/13/2023Richard G VincentCFOBuy1,500$6.00$9,000.00  
4/12/2023Chase C LeavittGeneral CounselBuy750$5.80$4,350.00  
4/12/2023Salim YazjiInsiderBuy500$5.60$2,800.00  
(Data available from 1/1/2013 forward)

ONCT Insider Trading Activity - Frequently Asked Questions

The list of insiders at Oncternal Therapeutics includes Chase C Leavitt, David F Hale, Gunnar F Kaufmann, James B Breitmeyer, Richard G Vincent, Robert James Wills, and Salim Yazji. Learn more on insiders at ONCT.

11.20% of Oncternal Therapeutics stock is owned by insiders. Learn more on ONCT's insider holdings.

The following insiders have purchased ONCT shares in the last 24 months: David F Hale ($6,454.56), Gunnar F Kaufmann ($9,830.00), and Robert James Wills ($86,281.28).

Insiders have purchased a total of 12,114 ONCT shares in the last 24 months for a total of $102,565.84 bought.

Oncternal Therapeutics Key Executives



This page (NASDAQ:ONCT) was last updated on 4/16/2025 by MarketBeat.com Staff
From Our Partners